Get startedLog in
    Picture of Percheron Therapeutics logo

    PER — Percheron Therapeutics News Story

    0.000.00%
    au flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapNeutral
    All News

    Brief: Antisense Therapeutics Submits Clinical Trial Application For Atl1102 Phase Iib Dmd Trial In Europe

    Picture of Percheron Therapeutics logoPercheron Therapeutics
    18/12/2022 23:17
    Dec 19 (Reuters) - Antisense Therapeutics Ltd  ANP.AX :
    * CLINICAL TRIAL APPLICATION SUBMITTED FOR ATL1102 PHASE IIB
DMD
TRIAL CONDUCT IN EUROPE
    * CTA APPROVALS ARE EXPECTED TO COME THROUGH IN A STAGGERED
MANNER
IN EARLY 2023

Source text for Eikon:  ID:nASX81gN7f 
Further company coverage:  ANP.AX 
 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Percheron Therapeutics

    See all news